News

June 4, 2018

Votrient Maintenance Therapy Fails to Improve Survival in Advanced Ovarian Cancer Patients, Trial Results Show

News

Maintenance treatment with Votrient (pazopanib) does not extend the survival of newly diagnosed advanced ovarian cancer patients whose disease did not worsen after surgery and first-line chemotherapy, according to Phase 3 ... Read more

June 1, 2018June 6, 2018

European Commission Approves Clovis’ Rubraca for Recurrent Ovarian Cancer

News

The European Commission recently authorized Rubraca (rucaparib) for the treatment for women with recurrent BRCA-mutant ovarian cancer with relapsed or progressive disease. The recent approval is for the maintenance treatment of recurrent ... Read more

May 30, 2018January 9, 2019

Phase 3 Trial to Assess TTFields plus Taxol in Platinum-resistant Ovarian Cancer Patients

News

A Phase 3 clinical trial will investigate the impact of adding Tumor Treating Fields (TTFields), a method that uses electric fields to disrupt cell division, to Taxol (paclitaxel) for the treatment of ... Read more

May 25, 2018May 25, 2018

Mirvetuximab Soravtansine Combo Therapies Show Promise for Ovarian Cancer, Clinical Trial Shows

News

Combinations of mirvetuximab soravtansine (IMGN853) with either Avastin (bevacizumab) or Paraplatin (carboplatin) are showing promise in certain ovarian cancer patients, particularly those who received multiple prior lines of therapy, the investigational therapy’s developer, ImmunoGen, recently announced. ... Read more

May 23, 2018

Phase 2 Trial Seeking Patients for Zejula-Avastin Combo as Maintenance Therapy for Advanced Ovarian Cancer

News

Tesaro is recruiting for its Phase 2 trial testing its therapy Zejula (niraparib) plus Avastin (bevacizumab, Genentech) as a maintenance therapy for women with advanced ovarian cancer who achieved at least a ... Read more

May 21, 2018

Update on Apealea, Potential Ovarian Cancer Therapy, Set for ASCO 2018 in June

News

Apealea, a water-soluble formulation of the chemotherapy paclitaxel, is not inferior to the standard formulation, Taxol (cremophor- EL paclitaxel), and may even improve the survival of ovarian cancer patients who responded to platinum-based ... Read more

May 18, 2018

Protein Levels Could Replace Genetic Tests for Detecting ARID1A Mutations

News

A laboratory technique that measures protein levels in tissue samples — called immunohistochemistry (IHC) — is a quicker and less expensive alternative to detect ARID1A mutations in patients with ovarian and other ... Read more

May 16, 2018May 16, 2018

MAGENTA Study Seeks Women to Evaluate At-home Ovarian Cancer Genetic Test

News

The University of Texas MD Anderson Cancer Center is currently seeking women to enroll in the MAGENTA study to evaluate the first at-home test to assess the risk of ovarian cancer. ... Read more

May 14, 2018

Researchers Discover Mutations Behind Resistance to PARP Inhibitors Like Lynparza

News

Scientists have found mutations in the poly ADP-ribose polymerase (PARP) gene that cause resistance to PARP inhibitor therapies — such as Lynparza (olaparib) — in a mouse model and in one ... Read more

May 11, 2018

Lynparza Tablets Approved in EU to Treat Advanced, Platinum-sensitive Ovarian Cancers

News

The European Medicines Agency (EMA) has approved Lynparza (olaparib) tablets as a maintenance therapy for ovarian cancer patient who have relapsed, but have had a complete or partial response to platinum-based chemotherapy, and ... Read more